Medicine Design Automation Team Lead GlaxoSmithKline, England, United Kingdom
Over the past few years, GSK has significantly advanced it’s biopharmaceutical drug discovery process to accelerate cycle times and increase candidate quality. Biopharmaceutical drug discovery campaigns have routinely adopted a funnel approach where only a finite selection of leads can be characterised at each stage due to limitations of material availability and assay throughput. We will present how we have modernised and embedded automation to increase our screening capacity and remove time consuming make-test cycles. Investments have been made in automated sample preparation, assay miniaturization & improved data management strategies. We will present how these have allowed us to create a data-rich environment enabling selection of high-quality leads, acceleration of cycle times to candidate and reduction of time on manual tasks freeing up FTEs to focus on science.
